Loading...

EXAI - Exscientia plc

Analyst Downgrade Signal for 01-05-2024
Analyst Downgrade Signal: EXAI from Buy to Neutral by BofA Securities
Price Target: $11>>9



Stock Signal Information


Signal

Analyst Downgrade Stock
Report Date: 01-05-2024
Symbol: EXAI - Exscientia plc
Sector: Healthcare
Industry: Biotechnology
Analyst Downgrade Signal: EXAI from Buy to Neutral by BofA Securities
Price Target: $11>>9

  EXAI Technical Chart

Company Contact

Exscientia plc (EXAI)
The Schrödinger Building
Oxford,
Phone: 44 13 8220 2136
Website: http://www.exscientia.ai
CEO:


Company Profile

Exscientia plc, an artificial intelligence-driven pharmatech company, engages in discovering, designing, and developing drugs. It offers end-to-end solution of artificial intelligence and technologies for target identification, drug candidate design, translational models, and patient selection. Its platform allows to design candidate drug molecules, as well as to provide patients with drug therapies through AI guided assessment. The company was founded in 2012 and is headquartered in Oxford, the United Kingdom.